Human immunodeficiency virus type 1 gp120 induces apoptosis in human primary neurons through redox-regulated activation of neutral sphingomyelinase.
Human immunodeficiency virus type 1 (HIV-1) infection is known to cause disorders of the CNS, including HIV-associated dementia (HAD). HIV-1 coat protein gp120 (glycoprotein 120) induces neuronal apoptosis and has been implicated in the pathogenesis of HAD. However, the mechanism by which gp120 causes neuronal apoptosis is poorly understood. The present study underlines the importance of gp120 in inducing the production of ceramide, an important inducer of apoptosis, in human primary neurons. gp120 induced the activation of sphingomyelinases (primarily the neutral one) and the production of ceramide in primary neurons. Antisense knockdown of neutral (NSMase) but not acidic (ASMase) sphingomyelinase markedly inhibited gp120-mediated apoptosis and cell death of primary neurons, suggesting that the activation of NSMase but not ASMase plays an important role in gp120-mediated neuronal apoptosis. Similarly, the HIV-1 regulatory protein Tat also induced neuronal cell death via NSMase. Furthermore, gp120-induced production of ceramide was redox sensitive, because reactive oxygen species were involved in the activation of NSMase but not ASMase. gp120 coupled CXCR4 (CXC chemokine receptor 4) to induce NADPH oxidase-mediated production of superoxide radicals in neurons, which was involved in the activation of NSMase but not ASMase. These studies suggest that gp120 may induce neuronal apoptosis in the CNS of HAD patients through the CXCR4-NADPH oxidase-superoxide-NSMase-ceramide pathway.
Jana
Arundhati
A
Section of Neuroscience, Department of Oral Biology, University of Nebraska Medical Center, Lincoln, Nebraska 68583, USA.
Pahan
Kalipada
K
D017209:Apoptosis / Q000502:physiology*; D001921:Brain / Q000166:cytology; D002518:Ceramides / Q000096:biosynthesis; D004789:Enzyme Activation; D015696:Gene Products, tat / Q000502:physiology; D015699:HIV Envelope Protein gp120 / Q000502:physiology*; D015497:HIV-1 / Q000502:physiology*; D006801:Humans; D066298:In Vitro Techniques; D019255:NADPH Oxidases / Q000378:metabolism; D009474:Neurons / Q000201:enzymology / Q000378:metabolism / Q000502:physiology / Q000821:virology*; D020319:Oligodeoxyribonucleotides, Antisense; D010084:Oxidation-Reduction; D017382:Reactive Oxygen Species / Q000378:metabolism; D019718:Receptors, CXCR4 / Q000502:physiology; D013108:Sphingomyelin Phosphodiesterase / Q000378:metabolism*; D013481:Superoxides / Q000378:metabolism; D054322:tat Gene Products, Human Immunodeficiency Virus
D002518:Ceramides; D015696:Gene Products, tat; D015699:HIV Envelope Protein gp120; D020319:Oligodeoxyribonucleotides, Antisense; D017382:Reactive Oxygen Species; D019718:Receptors, CXCR4; D054322:tat Gene Products, Human Immunodeficiency Virus; D013481:Superoxides; D019255:NADPH Oxidases; D013108:Sphingomyelin Phosphodiesterase